- Home
- UWMC vs SEPN Comparison
UWMC vs SEPN Comparison
Compare UWMC & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- SEPN
- Stock Information
- Founded
- UWMC 1986
- SEPN 2022
- Country
- UWMC United States
- SEPN United States
- Employees
- UWMC N/A
- SEPN N/A
- Industry
- UWMC Finance: Consumer Services
- SEPN
- Sector
- UWMC Finance
- SEPN
- Exchange
- UWMC Nasdaq
- SEPN NYSE
- Market Cap
- UWMC 971.2M
- SEPN 1.0B
- IPO Year
- UWMC N/A
- SEPN 2024
- Fundamental
- Price
- UWMC $5.89
- SEPN $24.28
- Analyst Decision
- UWMC Hold
- SEPN Strong Buy
- Analyst Count
- UWMC 8
- SEPN 4
- Target Price
- UWMC $7.41
- SEPN $43.67
- AVG Volume (30 Days)
- UWMC 3.1M
- SEPN 464.1K
- Earning Date
- UWMC 11-07-2024
- SEPN 02-15-2025
- Dividend Yield
- UWMC 6.80%
- SEPN N/A
- EPS Growth
- UWMC N/A
- SEPN N/A
- EPS
- UWMC N/A
- SEPN N/A
- Revenue
- UWMC $2,727,467,000.00
- SEPN $981,000.00
- Revenue This Year
- UWMC $2.19
- SEPN $406.62
- Revenue Next Year
- UWMC $26.43
- SEPN N/A
- P/E Ratio
- UWMC N/A
- SEPN N/A
- Revenue Growth
- UWMC 29.95
- SEPN N/A
- 52 Week Low
- UWMC $5.44
- SEPN $18.62
- 52 Week High
- UWMC $9.74
- SEPN $27.47
- Technical
- Relative Strength Index (RSI)
- UWMC 40.82
- SEPN N/A
- Support Level
- UWMC $5.44
- SEPN N/A
- Resistance Level
- UWMC $6.48
- SEPN N/A
- Average True Range (ATR)
- UWMC 0.27
- SEPN 0.00
- MACD
- UWMC -0.04
- SEPN 0.00
- Stochastic Oscillator
- UWMC 37.71
- SEPN 0.00
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale and servicing of residential mortgage loans. The company provides independent mortgage advisors across the states and the district of Columbia.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.